Oncotarget · 2017 · 14 citations · 42 references
MedicineCancer BiologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer BiomarkersCancer Cell SignalingCancer Survival AnalysisChemokine NetworksChemokine SignalingMalignant NeoplasmsC-c Chemokine Receptor 2 SignalingChemokines In Tumor ProgressionDisease-free Survival AnalysisDisease-free Survival AssessmentPrognostic Expression SignaturesPrognostic Tumor MarkersRecurrence-free SurvivalSystematic Review Retrieval
// Yong Yang 1, * , Baoyang Luo 1, * , Yong An 1 , Han Sun 2 , Huihua Cai 1 and Donglin Sun 1 1 Department of Hepatobiliary Pancreatic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, People’s Republic of China 2 Department of Orthopedic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, People’s Republic of China * These authors contributed equally to this work Correspondence to: Donglin Sun, email: czsdl@sina.com Keywords: CXCR2, survival, solid tumor, biomarker, meta-analysis Received: July 03, 2017 Accepted: October 02, 2017 Published: November 03, 2017 ABSTRACT CXC chemokine receptor-2 (CXCR2) expression is associated with the prognosis of multiple cancers. We performed a meta-analysis to determine the association between the CXCR2 expression in tumor tissue and patient prognosis. We compiled related literature from PubMed, Embase, and Web of Science (last updated July 31, 2017). A total of 4012 patients with solid tumors from 21 studies were included to evaluate the association between CXCR2 and overall survival, recurrence-free survival, or disease-free survival. High CXCR2 expression was significantly associated with poor overall survival (pooled HR = 1.82; 95% CI = 1.63–2.03; P < 0.001), recurrence-free survival (pooled HR = 1.40; 95% CI = 1.21–1.62; P < 0.001), and disease-free survival (pooled HR = 1.89; 95% CI = 1.05–3.40; P = 0.033), especially in patients with digestive system neoplasms. Thus high CXCR2 expression in tumor tissue appears predictive of a poor prognosis in patients with solid tumors. Further studies will be required to determine whether CXCR2 blockade has a favorable effect on the prognosis of patients with cancer.
42
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Assessing Bias in Studies of Prognostic Factors
Jill A. Hayden, Daniëlle van der Windt, Jennifer Cartwright et al. · Annals of Internal Medicine · 2013 · 3.1K citations